Dr. Stacy Loeb on Considerations for Screening in Prostate Cancer

Stacy Loeb, MD
Published Online: Friday, Sep 23, 2016


Stacy Loeb, MD, assistant professor of urology and population health at New York University (NYU) Langone Medical Center, discusses screening determinations for prostate cancer.
 
It is important that patients receive a baseline measurement of PSA in their 40s. What that level is in a younger man actually gives oncologists an idea as to what their life risk of having life-threatening prostate cancer is.
 
To reduce the downstream harm from screening, oncologists need to be selective about treatment, says Loeb.
 
Active surveillance is really on the rise in both Europe and in the United States. Saving aggressive treatment for aggressive cancer, and encouraging active surveillance for low-risk disease can reduce the risks of overtreatment.
 
 

Stacy Loeb, MD, assistant professor of urology and population health at New York University (NYU) Langone Medical Center, discusses screening determinations for prostate cancer.
 
It is important that patients receive a baseline measurement of PSA in their 40s. What that level is in a younger man actually gives oncologists an idea as to what their life risk of having life-threatening prostate cancer is.
 
To reduce the downstream harm from screening, oncologists need to be selective about treatment, says Loeb.
 
Active surveillance is really on the rise in both Europe and in the United States. Saving aggressive treatment for aggressive cancer, and encouraging active surveillance for low-risk disease can reduce the risks of overtreatment.
 
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Optimizing Treatment and Management of Soft Tissue Sarcoma in Community OncologyNov 30, 20171.5
Community Practice Connections™: 1st Annual European Congress on Immunotherapies in Cancer™Dec 13, 20171.5
Publication Bottom Border
Border Publication
x